Keyphrases
Left Ventricular Assist Device
55%
Left Ventricular Assist Device Implantation
36%
Left Ventricular Assist Device Support
29%
Heart Transplantation
25%
Continuous-flow Left Ventricular Assist Device (CF-LVAD)
22%
HeartMate 3
17%
Acute Decompensated Heart Failure
12%
Pulmonary Hypertension
12%
Pectoral muscle
12%
Hazard Ratio
12%
Bridge to Transplantation
12%
Right Heart Failure
12%
Heart Failure with Preserved Ejection Fraction (HFpEF)
11%
Heart Failure
11%
Mechanical Circulatory Support
10%
Gastrointestinal Bleeding
10%
Lung Transplantation
10%
MOMENTUM 3
9%
Heart Transplant
9%
Destination Therapy
9%
Confidence Interval
9%
Patient Management
9%
Risk Score
9%
Pulmonary Arterial Hypertension
9%
Cardiogenic Shock
8%
Heart Allocation Policy
8%
Clinical Outcomes
8%
Cardiac Transplantation
8%
HeartMate II
7%
Cardiomyopathy
7%
Adverse Events
7%
Maglev Technology
7%
United States
7%
Device Complications
6%
Supportive Therapy
6%
Magnetically Levitated
6%
INTERMACS
6%
Long-term Survival
6%
Implantable Defibrillator
6%
Prediction Model
6%
Durable Mechanical Circulatory Support
6%
1-year Survival
6%
Quality of Life
6%
Minnesota
6%
Low Dose Rate
5%
Transplantation
5%
Pulmonary Artery
5%
Expert Consensus Statement
5%
Medical Management
5%
Atherosclerotic Risk Factors
5%
Medicine and Dentistry
Left Ventricular Assist Device
100%
Congestive Heart Failure
43%
Heart Transplantation
30%
Assisted Circulation
23%
Apoplexy
19%
Hazard Ratio
16%
Heart Right Ventricle Failure
14%
Heart Graft
14%
Pulmonary Hypertension
12%
Gastrointestinal Bleeding
11%
Lung Transplantation
9%
Atherosclerosis
8%
Cardiogenic Shock
8%
Adverse Event
7%
Quality of Life
7%
Myocardial Disease
6%
Implantable Automatic Defibrillator
6%
Long Term Survival
6%
Reoperation
6%
Implant
6%
Heart Failure with Preserved Ejection Fraction
5%
Meta-Analysis
5%
Systematic Review
5%
Cardiac Sarcoidosis
5%
Positron Emission Tomography-Computed Tomography
5%
Fluorodeoxyglucose F 18
5%
Survival Rate
5%
Pulmonary Artery
5%
Proportional Hazards Model
5%
Hemodynamic
5%
Surgeon
5%